Research dossier

TB-500 — actin sequestration dossier

An actin-sequestering peptide, studied for cytoskeletal reorganisation in culture.

6 min read · Purpeptide Research Desk ·

Translated from the French original, which remains the reference version: lire en français →

TB-500 — research dossier illustration

Molecular identity

ParameterValue
CAS number77591-33-4
Molar mass4963.4 g/mol
Molecular formulaC₂₁₂H₃₅₀N₅₆O₇₈S
Sequence / natureAc-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Purity≥99%
AppearanceWhite lyophilised powder

The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.

Research context

The scientific interest lies less in the fragment than in the actin sequestration mechanism, which is an object of study in cell biology independently of any application. Actin polymerisation assays followed by fluorescence are a long-standing and well standardised method, which makes this area relatively robust compared with others covered in this catalogue.

Mechanism studied

TB-500 corresponds to a sequence derived from thymosin beta-4, a 43 amino acid protein described as the principal sequestering agent of monomeric actin (G-actin) in mammalian cells.

The documented mechanism is physico-chemical before it is signalling: thymosin beta-4 binds G-actin and constitutes a reservoir of non-polymerisable monomers. By altering the balance between monomeric actin and filamentous actin (F-actin), it influences the speed at which the cytoskeleton can be reorganised — a determining step in cell motility.

Published in-vitro work has measured this interaction by actin polymerisation assays followed by fluorescence (pyrene-labelled actin), a method that allows the G/F ratio to be quantified directly in real time. Other work has examined the migration of endothelial cells and keratinocytes in culture, together with the expression of markers associated with new vessel formation in three-dimensional models.

In-vitro literature

The literature clearly separates the whole protein from the synthetic fragment, and results obtained with one are not transferable to the other without verification. That distinction matters methodologically when comparing results between publications.

Bibliographic entry points

These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.

Distinguishing this compound from its analogues

Not to be confused with thymosin alpha-1, a peptide with no structural or functional relationship despite the similarity of the names.

The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.

Methodological limits

The most frequent confusion in the literature concerns which entity was studied: whole thymosin beta-4 or the synthetic fragment. Results are not transferable from one to the other, and many publications do not state this clearly enough. Critical reading requires checking the exact sequence used every time.

These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.

Analytical parameters

A high molecular mass for a synthetic peptide. Checking quantitative content per vial is particularly relevant here, the gap between weighed mass and actual peptide mass being accentuated by counter-ion and residual water content.

ParameterValue
StorageStore at −20 °C, protected from light
SolubilitySoluble in bacteriostatic water (BAC)
StabilityStable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C
Control methodsRP-HPLC · MS · NMR

Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.

Resulting concentrations

The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.

Format1 ml2 ml3 ml
10mg10.00 mg/ml5.00 mg/ml3.33 mg/ml

These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.

Protocol design

Three points govern the validity of an assay using this material, whatever the question being asked.

The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.

The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.

The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.

Lot verification

The following formats are covered by a Janoshik Analytical report, readable from the product page:

  • 10mg — lot report available
FormatLot reportAvailability
10mgCoveredIn stock

The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.

Frequently asked questions

How does this product arrive?

As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.

Which solvent should be used for reconstitution?

Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.

How long does the material remain stable?

The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.

Does the analysis report correspond exactly to my vial?

The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.

Can this product be used on humans or animals?

No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.

See also: BPC-157 or TB-500: the comparison

Dossiers in the same category

Related dossiers

All research dossiers → · Catalogue → · Glossary →